0001437749-23-014291.txt : 20230616 0001437749-23-014291.hdr.sgml : 20230616 20230515060453 ACCESSION NUMBER: 0001437749-23-014291 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20230515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SAB Biotherapeutics, Inc. CENTRAL INDEX KEY: 0001833214 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 853899721 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 2100 EAST 54TH STREET NORTH CITY: SIOUX FALLS STATE: SD ZIP: 57104 BUSINESS PHONE: 605-679-6980 MAIL ADDRESS: STREET 1: 2100 EAST 54TH STREET NORTH CITY: SIOUX FALLS STATE: SD ZIP: 57104 FORMER COMPANY: FORMER CONFORMED NAME: Big Cypress Acquisition Corp. DATE OF NAME CHANGE: 20201120 CORRESP 1 filename1.htm sabs20230512_corresp.htm

May 15, 2023

 

 

VIA EDGAR

 

Division of Corporation Finance

Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

Attention: Daniel Crawford

 

 

RE:

SAB Biotherapeutics, Inc.
Registration Statement on Form S-3

File No. 333-271768

Filed May 9, 2023

 

In accordance with Rule 461 of the Rules and Regulations promulgated under the Securities Act of 1933, as amended, SAB Biotherapeutics, Inc. (the “Registrant”) hereby respectfully requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement to Wednesday, May 17, 2023 at 5:00 p.m., Eastern Time, or as soon as thereafter practicable.

 

Please call Ilan Katz of Dentons US LLP at (212) 632-5556 to confirm the effectiveness of the Registration Statement or with any questions.

 

 

Very truly yours,
   
 

SAB Biotherapeutics, Inc.
   
 

/s/ Eddie J. Sullivan

 

Eddie J. Sullivan
 

Chief Executive Officer

 

 

cc:

Ilan Katz, Dentons US LLP